Concepedia

Author

Sabine Bauer

Roche Pharma AG (Germany)

Also Known As

Bauer, Sabine, S Kasimir Bauer, SJ. Bauer, Sabine Bauer

35

Publications

1.3K

Citations

10

H-Index

15

Concepts

All Affiliations

Roche Pharma AG (Germany)Medical University of ViennaUniversity Medical Center GroningenRoche (Switzerland)University of Vienna
SB

About

Sabine Bauer is an author at Roche Pharma AG (Germany) specializing in medicine, pharmacology, and allergy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

137

2

Allergy

1

1

44

3

Cell Biology

1

1

51

4

Critical Care Medicine

1

1

42

5

Emergency Medicine

1

1

42

Sabine Bauer

×

9

Publications

1.2K

Citations

9

H-Index

YearCitations

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Ekkehard Mössner, Peter Brünker, Samuel Moser,

Blood

2010

929

Novel 3rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction.

Pablo Umaña, Ekkehard Moessner, Peter Bruenker,

Blood

2006

52

Berberine and a Berberis lycium extract inactivate Cdc25A and induce α-tubulin acetylation that correlate with HL-60 cell cycle inhibition and apoptosis

Musa Khan, Benedikt Giessrigl, Caroline Vonach,

Mutation research. Fundamental and molecular mechanisms of mutagenesis

2009

51

In vitro anti-leukemic activity of the ethno-pharmacological plant Scutellaria orientalis ssp. carica endemic to western Turkey

Ali Özmen, Sibylle Madlener, Sabine Bauer,

Phytomedicine

2009

44

Outcome and functional capacity after prolonged intensive care unit stay

Georg Delle Karth, Brigitte Meyer, Sabine Bauer,

Wiener klinische Wochenschrift

2006

42

ATMIN is required for the ATM-mediated signaling and recruitment of 53BP1 to DNA damage sites upon replication stress

Luisa Schmidt, Marc Wiedner, Georgia Velimezi,

DNA repair

2014

33

Pro- and anticarcinogenic mechanisms of piceatannol are activated dose dependently in MCF-7 breast cancer cells

Nha T.P. Vo, Sibylle Madlener, Zsuzsanna Bagó-Horváth,

Carcinogenesis

2009

28

GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo.

Pablo Umaña, Ekkehard Moessner, Peter Bruenker,

Blood

2007

22

GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Mediates Superior Efficacy in a Variety of NHL Xenograft Models in Comparison to Rituximab.

Thomas Friess, Christian Gerdes, Adam Nopora,

Blood

2007

10

Page 1